ERBB2 and inflammatory breast carcinoma: Palazzo et al. [35] enrolled HER2-positive (n = 14) and HER2-negative (n = 20) IBC patients and treated them with chemotherapy with bevacizumab, with trastuzumab added for HER2-positive disease.